acyl-CoA synthetase long chain family member 3Genealiases: ACS3 · FACL3 · LACS 3 · LACS3 · PRO2194
Q-omics provides the consensus-scored ACSL3 profile across patient tissues and cancer cell-line models. ACSL3 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ACSL3 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, ACSL3 RNA expression shows 20,160 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where ACSL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACSL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACSL3 survival associations across molecular data types. ACSL3 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACSL3 RNA expression–survival associations across cancer types. High ACSL3 expression shows unfavorable associations in UVM, HNSC, LIHC, LUAD and MESO, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ACSL3 RNA expression.
This table summarizes ACSL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ACSL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACSL3 shows lower tumor expression in KIRC, THCA and KIRP and higher tumor expression in LIHC, COAD and CHOL. The KIRC box plot shows higher ACSL3 RNA expression in normal versus tumor tissue (log2 FC = −0.884, t-test p < 0.001).
This table shows molecular features associated with ACSL3 in patient tissues and cancer cell lines. In patient samples, ACSL3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ACSL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
